Alzheimer's disease (AD) is a prominent form of dementia, characterized by aggregation of the amyloid β-peptide (Aβ) plaques and neurofibrillary tangles, loss of synapses and neurons, and degeneration of cognitive functions. Currently, although a variety of medications can relieve some of the symptoms, there is no cure for AD. Recent breakthroughs in the stem cell field provide promising strategies for AD treatment. Stem cells including embryonic stem cells (ESCs), neural stem cells (NSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs) are potentials for AD treatment. However, the limitation of cell sources, safety issues, and ethical issues restrict their applications in AD. Recently, the direct reprogramming of induced neural progenitor cells (iNPCs) has shed light on the treatment of AD. In this review, we will discuss the latest progress, challenges, and potential applications of direct reprogramming in AD treatment.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Lai, Siqiang; Zhang, Min; Xu, Dongsheng; Zhang, Yiying; Qiu, Lisha; Tian, Changhai; and Zheng, Jialin Charlie, "Direct reprogramming of induced neural progenitors: a new promising strategy for AD treatment." (2015). Journal Articles: Pharmacology & Experimental Neuroscience. 45.